Rising Disease Prevalence to Drive Age-Related Macular Degeneration Market Forward

Registering a CAGR of 7.6% during the forecast period (2016–2022), the global age-related macular degeneration (AMD) market is projected to garner $8.9 billion by 2022, significantly growing from $5.3 billion in 2015. The market is experiencing growth due to the rising geriatric population, growing pipeline for AMD therapeutics, surging chronic disease prevalence, and increasing healthcare expenditure. Age-related macular degeneration is a retinal disorder, which is indicated by changes in the fundus of the eye. It commonly affects the elderly, in which, first, the central vision becomes blurred, which ultimately leads to blindness. 

Based on type, the age-related macular degeneration market is bifurcated into wet AMD and dry AMD. Between the two, during the historical period (2012–2015), the larger revenue in the market was generated by the wet AMD type. This type of AMD is caused due to the abnormal growth of blood vessels from the choroid layer, which is situated beneath the macula. It is also known as neovascular macular degeneration, and even though it accounts for only 10–15% of AMD cases, it is expected to be the faster growing category in the forecast period.

Access Detailed Report - Age-Related Macular Degeneration Market Regional and Country Breakdown

With the rising awareness about the disease, more funding is being allocated in the research and development of AMD therapeutics. This is resulting in the increase in the number of AMD pipeline drugs. Currently, the U.S. Food and Drug Administration has not approved any drug in the age-related macular degeneration (AMD) market for dry age-related macular degeneration. Therefore, the need to investigate more compounds with possible therapeutics properties is rising. Some of the major investigational compounds in the market are Roche/Genentech’s lampalizumab, MacuCLEAR’s MC1101, and Allergan’s brimonide implant.

Therefore, the market for age-related macular degeneration is predicted to register remarkable growth in the forecast period with the rising prevalence of this disease and surging geriatric population.

Read More

Increasing Prevalence of Benign Prostatic Hyperplasia in American Men Driving Demand for BPH Treatment Procedures

Benign Prostatic Hyperplasia (BPH) is a medical condition in which the prostate gland becomes enlarged. The enlargement of the prostate gland causes urinary tract problems by blocking the flow of urine out of the body. This happens because the prostate gland surrounds the urethra, which is the tube that carries the urine from the urinary bladder to out of the body, and so, the enlargement of the gland squeezes or blocks the urethra, causing discomfort and problems while urinating.

Receive Sample Copy of this Report: https://www.psmarketresearch.com/market-analysis/us-bph-procedures/report-sample

In the U.S., the growing prevalence of this diseases, because of the surging geriatric population in the country, is rapidly becoming a major health issue. As a result, medical researchers are conducting extensive research and development (R&D) activities for developing advanced BPH treatment procedures. Moreover, the demand for BPH medications is also rising at an explosive pace in the country. Because of these factors, the U.S. benign prostatic hyperplasia (BPH) procedures market will advance rapidly in the coming years.

Amongst the various energy-based treatment procedures, the popularity of the laser-based procedures was found to be very high in the years gone by, because of the fact that these procedures are much more effective than the traditional treatment methods and are far less likely to cause various complications such as bleeding. There are many types of laser-based treatment procedures such as those involving thulium-, holmium lasers-, and green light lasers.

Make an Enquiry before Purchase:https://www.psmarketresearch.com/market-analysis/us-bph-procedures/report-sample

Therefore, it can be said with complete certainty that the demand for benign prostatic hyperplasia treatment (BPH) procedures will rise enormously in the U.S. in the upcoming years, because of the growing prevalence of BPH in males and the rapid advancements and innovations being made in these procedures in the country.

Read More

Pain Management Drugs Market Segmental Analysis by Therapeutics, Diagnostics, Patient, Drugs Policy and Regulatory Landscape

The growing geriatric population and increasing demand of innovative and advanced pain relaxing medications around the world are the predominant growth drivers for the global pain management drugs market. Additionally, the increasing number of hospitalization cases; unmet requirements for neuropathic pain management drugs; innovative and advanced applications of pain management therapies; increasing prevalence of various chronic diseases, such as cancer, and neurological problems; and increasing healthcare expenditure are also driving the growth of the global market. The growing numbers of mergers and acquisitions is a key trend observed in the market. Among the various therapeutic indications, the post-operative pain relief segment accounted for the largest share, and the low-back pain segment accounted for the second largest share in the global market.

Pain management drugs are mainly used to relieve discomfort associated with injury and surgeries. Moreover, pain management medications are used in the management of pain associated with neurological problems, migraine, cancer, orthopedic problems, low- back pain, rheumatoid arthritis, and fibromyalgia.

Request to Get the Sample Pages at: 

North America and Europe are the major markets, due to increasing prevalence of chronic diseases, and growing awareness about various types of chronic pain conditions in these regions. The U.S. followed by Canada, is the largest market for pain management drugs in North America. Whereas, the U.K., Germany and France are some of the major countries holding significant share in the European pain management drugs market.

The Asian market is growing with a significant rate, owing to huge pool of patients, and increasing healthcare spending in the region. In addition, the initiatives taken by various government associations to develop chronic pain rehabilitation centers, and increasing prevalence of various chronic diseases are also supporting the growth of the Asian pain management drugs market. The countries such as India, Japan and China, are the major markets in the region.

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=pain-management-drugs-market

Apart from these regions, Latin America is another important market. This is due to increasing investments by drug manufacturing companies and growing demand of pain management medications in the region. Brazil holds the largest share in the Latin American pain management drugs market, due to the increasing support from government organizations for the development of chronic pain rehabilitation center in the country.

Some of the major players operating in the global pain management drugs market include Purdue Pharma L.P., Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, Forest Laboratories Inc., Endo International PLC, Johnson & Johnson, Pfizer Inc., Valeant Pharmaceuticals International Inc., GlaxoSmithKline PLC, F. Hoffmann-La Roche Ltd., and Baxter International Inc.

Pain Management Drugs Market Segmentation

By Category

•              Prescription-Based Drugs

•              Over-The-Counter (OTC) Drugs

By Therapeutic Indications

•              Post-Operative Pain

•              Low-Back Pain

•              Rheumatoid Arthritis Pain

•              Osteoarthritis Pain

•              Cancer Pain

•              Migraine

•              Neuropathic Pain

•              Fibromyalgia

•              Others

By Brands

•              Maxalt

•              Zomig

•              Qutenza

•              Lidoderm

•              Savella

•              Imitrex

•              Voltaren Gel

•              Celebrex

•              Cymbalta

•              Others

By Geography

•              North America

o              U.S.

o              Canada

•              Europe

o              Germany

o              France

o              U.K.

o              Spain

o              Italy

•              Asia

o              Japan

o              China

o              India

•              Latin America

o              Brazil

•              Rest of the World

Read More

Glaucoma Therapeutics Market Demand, Developments, Industry Opportunities and Industry Research Report

Glaucoma is a disease of eye which is caused by excessive increase of fluid pressure within the eye. Glaucoma is caused due to mechanical compression or decreased blood flow in the optic nerve of the patient’s eye. If not treated properly, it may lead to mild loss of vision and even blindness. Treatment of glaucoma includes laser therapies, pharmaceutical drugs and surgical procedures.

Ocular hypertension is one of the major causes due to which glaucoma occurs in patients. Glaucoma mostly occurs at the age over 40, but it may also occur in children, young adults, and infants. Diagnosis of glaucoma can be done through a simple eye examination with the help of tonometry, an instrument used for measuring intraocular pressure, by an ophthalmologists and optometrist. Prevention of glaucoma is difficult; however, if diagnosed and treated at an early stage, the disease can be controlled by using eye drops prescribed by doctor, microsurgery or by laser surgery. Glaucoma can damage the vision of the affected eye permanently; in first stage it decreases the peripheral vision and if not treated, it can lead to blindness.

Request to Get the Sample Pages at:

Some of the major factors driving the growth of glaucoma therapeutics market are aging population of developed countries, development of advanced glaucoma drug delivery devices and rising global healthcare expenditures. Stringent government regulation and marketing approval, side effects of glaucoma medications and long development process of the glaucoma products are some of the major factors restraining the growth of global glaucoma therapeutics market.

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=glaucoma-therapeutics-market

North America was the largest glaucoma therapeutics market in 2014, attributed to high per capita expenditure on healthcare in this region. It is followed by Europe and Asia-Pacific. Asia-Pacific region is also the fastest growing glaucoma therapeutics market, owing to the aging population of Japan coupled with the increasing healthcare expenditure of developing countries, such as India and China. Asia-Pacific glaucoma therapeutics market is further expected to witness growth and surpass North America market in terms of largest market during the coming years.

Some of the major competitors in global glaucoma therapeutics market are Pfizer Inc., Allergen Inc., Novartis A.G., Merck & Co. Inc., Aerie Pharmaceuticals Inc., Inotek Pharmaceuticals Corp., Carl Zeiss Meditec Inc., Acadia Pharmaceuticals Inc., Neurotech Pharmaceuticals Inc., NicOx SA, Santen Pharmaceuticals Co. Ltd., Otsuka Holdings Co. Ltd., SIFI SpA, and Valeant Pharmaceuticals International Inc.

Read More

Testicular Cancer Therapeutics Market - Epidemiology Analysis, Therapy, Development, Growth and Demand

Global testicular cancer therapeutics market is growing with the increasing prevalence of testicular cancer. The market is expected to witness moderate growth, since there are already more than 15 drugs that exist in the market for the treatment of testicular cancer. Increasing prevalence of cancer and rising demand for the medications with better efficacy and less side effects can be attributed as an opportunity for oncology. The regulatory bodies such as USFDA, EMA are supporting the growth of the global market by providing increased funding, designations and grants for speeding up the drug development process. 

Testicular cancer is the tumor that develops in the testicles. Testicles are the glands found in men that produce testosterone hormone and sperms. The cause of testicular cancer is attributable to enormous growth of testicular cells due to some abnormalities, resulting in the formation of tumor in testicles, causing testicular cancer. Cryptorchidism, inguinal hernia, congenital abnormalities, abnormal testicular development and family history can increase the risk of testicular cancer. Mumps orchitis are also one of risk factors which is a very rare complication of mumps, which involves the inflammation of testicles. Pain, swelling, discomfort, sensation of heaviness and sudden fluid accumulation in scrotum are the main symptoms of testicular cancer.

Request to Get the Sample Pages at: 

Growing prevalence of testicular cancer and combination therapies for the treatment are the major driving forces for the testicular cancer therapeutics market. Also with no drug in Phase III, there is a need for growth in pipeline for better treatment options, providing increased opportunities to the players in the market. Some of the marketed drugs for the treatment of testicular cancer include Blenoxane (Bleomycin), Cisplatin, Cosmegen (Dactinomycin), Cyfos (Ifosfamide), Etopophos (Etoposide Phosphate) and Velban (Vinblastine Sulfate). Some of the drug combination available in the market are BEP, JEB, PEB, VIP and VeIP.

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=testicular-cancer-therapeutics-market

The treatment is more effective if the chemotherapy regimen involves two or more drugs rather than using any single drug. Therefore, chemotherapy is expected to have major share in the global testicular cancer therapeutics market.

Some of the key players operating in the global testicular cancer therapeutics market are Ovation Pharmaceuticals, Inc., ZIOPHARM Oncology Inc., Bristol-Myers Squibb Company, Hospira Inc., Teva Pharmaceutical Industries Ltd., Fresenius Kabi AG and Teva Parenteral Medicines, Inc.

Read More

Esophageal Cancer Therapeutics Market - Epidemiology Analysis, Therapy, Development, Growth and Demand Forecast to 2024

Global esophageal cancer therapeutics market is expected to witness significant growth with an increasing awareness regarding cancer treatment and technological advancements. Also, high demand for safe and effective medications and rising prevalence of cancer are driving the growth of the global market. The regulatory bodies such as USFDA, EMA are supporting the growth of the global market by providing funding, designations and grants for speeding up the drug development process.

Esophageal cancer involves formation of malignant cells in the tissues of the esophagus. Esophagus is a muscular tube that enable food and liquids to move from the throat to the stomach. The main types of esophageal cancer are adenocarcinoma and squamous cell carcinoma. Adenocarcinoma forms in cells that produce and release mucus and other fluids. Squamous cell carcinoma forms in flat cells lining the esophagus. Esophageal squamous cell carcinoma includes heavy alcohol consumption and smoking as major risk factors, with gastroesophageal reflux disease and Barrett esophagus further contributing as the risk factors of esophageal adenocarcinoma. Esophageal cancer has no early signs or symptoms; therefore, an advanced stage diagnosis is difficult.

Request to Get the Sample Pages at: 

Some of the major drivers for the global esophageal cancer therapeutics market include combination therapies, treatment advancements, increasing number of regulatory approvals for esophageal cancer and a rise in the number of cancer treatment centers. Moreover, the launch of new drug therapies for esophageal cancer is expected to contribute as a key market driver in the near future. Also with a dense pipeline, many new drug candidates are expected to enter the global esophageal cancer therapeutics market. Safety concerns and efficacy of the treatment are the major factors that can hinder the market growth over the forecast period. Other factors hampering the market growth include low availability of drugs commercially and high cost of therapy for the treatment of esophageal cancer.

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=esophageal-cancer-therapeutics-market

Certain chemotherapy medications such as Doxorubicin, Bleomycin, Vinblastine, Dacarbazine, Chlorambucil, Procarbazine Prednisolone, Mustine, Vincristine, Etoposide, Cyclophosphamide, Gemcitabine, Cisplatin and Cytarabine are well established as a conventional method. Immunotherapy, combination therapy, monoclonal antibodies and steroids have also been showing good results for the treatment of esophageal cancer.

Some of the key players operating in the global esophageal cancer therapeutics market include Genentech, Inc., Sanofi-Aventis, Eli Lilly and Company, Ono Pharmaceutical Co., Ltd., Merck & Co., Inc., Johnson & Johnson Pharmaceutical Research & Development, LLC, Gilead Sciences, and Bristol-Myers Squibb, among others.

Read More

Oropharyngeal Cancer Therapeutics Market Segmental Analysis by Therapeutics, Diagnostics, Patient, Drugs Policy and Regulatory Landscape

The global oropharyngeal cancer therapeutics market is expected to have significant growth since the pipeline for oropharyngeal cancer is growing rapidly.

Also, there are no specific drugs available for the treatment of oropharyngeal cancer providing increased opportunities for the major key players.

Oral cavity tumor or oral tumor, is tumor that begins in the mouth (also known as the oral cavity). Oropharyngeal malignancy begins in the oropharynx, which is the part of the throat behind the mouth. The oral cavity comprises of lips, the inside lining of the lips and cheeks (buccal mucosa), the teeth, the gums, the front two-thirds of the tongue, the floor of the mouth below the tongue and the bony roof of the mouth (hard palate). The area behind the wisdom teeth, called the retromolar trigone is also sometimes included in the oral cavity, though it is often considered part of the oropharynx.

                                                                Request to Get the Sample Pages at:

The oropharynx is the part of the throat just behind the mouth and begins where the oral cavity stops. It comprises of base of the tongue (the back third of the tongue), the soft palate (the back part of the roof of the mouth), the tonsils, and the side and back wall of the throat.

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=oropharyngeal-cancer-therapeutics-market

The oropharyngeal cancer therapeutics market is segmented based on the therapy which includes surgery, chemotherapy, radiation therapy, targeted therapy and palliative treatment. Chemotherapy holds the largest share since it contains maximum number of drugs including, Cisplatin, Carboplatin, 5-fluorouracil (5-FU), Paclitaxel (Taxol) and Docetaxel (Taxotere). The palliative treatment segment holds the second largest share including, ibuprofen, acetaminophen, morphine or similar drugs. Targeted therapy holds the lowest share and includes only one drug, Cetuximab which may be combined with radiation therapy.

Some of the key players operating in the oropharyngeal cancer therapeutics market include Genticel S.A., AstraZeneca Plc, Kolltan Pharmaceuticals Inc., PNP Therapeutics Inc., Novartis AG, Advaxis Inc., Merck & Co. Inc., VLPbio and Synta Pharmaceuticals Corp.

Read More

Influenza Vaccine Market by Therapeutics, Diagnostics, Patient, Drugs Policy and Regulatory Landscape

The global influenza vaccine market is growing significantly due increasing awareness about the pandemic influenza viruses and increasing government involvement for vaccination against influenza viruses.Massive unexplored influenza vaccine marketin the emerging economiesare creating ample opportunities for the global influenza vaccine marketto grow at a significant rate in the forecasted period.The advanced research and development facilities and new vaccine developments by the companies are propelling the demand for safe and efficacious influenza vaccine. Influenza (flu) is a respiratory disease caused by mainly two types of influenza viruses namely, influenza A and B viruses. Influenza A viruses are of two types based on the proteins on the surface of virus: hemagglutinin (H) and neuraminidase (N).

In global influenza vaccine industry, there is a trend of development of intranasal vaccine due to the ease of self administration. According to Centers for Disease Control and Prevention (CDC),in 2009, approximately 151,700 to 575,400 people died due to H1N1 influenza pandemic or swine flu across the globe. In addition, the organization also reported that most deaths due to 2009 flu pandemic occurred in Africa and Southeast Asia region. Several vaccines have been developed to prevent pandemic and seasonal influenza viruses using recombinant DNA technology and extensive researches are going on to develop efficient influenza vaccines using cell culture technology. Various governmental and non-governmental organizations have been actively involved in promoting and monitoring vaccination programs aimed at immunising people against seasonal influenza viruses. This in turn fuels the growth of global influenza vaccine market.

Request to Get the Sample Pages at:

 Some of the factors driving the growth of the global influenza vaccine market are increasing research and development activities,increasing investment by companies for the development of influenza vaccine, technological advancements in recombinant DNA technology, large number of population with no immunization against influenza viruses in emerging economies,increasing healthcare expenditure, and increasing involvement of government and non-government organizations.In addition, geriatric population and people suffering from chronic diseases are at higher risk of developing influenza virus infection; hence, aging population and increasing prevalence of chronic diseases are also driving the demand of influenza vaccine market. However, stringent regulatory framework and low accessibility to remote areas aresome of the factors restraining the growth of the global influenza vaccine market to some extent.

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=influenza-vaccine-market

Geographically, North America will be leading the global influenza vaccine market in the coming years, due to high awareness of influenza viruses, high healthcare expenditure, and increasing research and development activities.In addition, the U.S. Food and Drug Administration (FDA), recommends vaccination as the most effective method to prevent influenza; hence, fueling the growth of influenza vaccine market in NorthAmerica region. Asia-Pacificis the fastest growing region in the global influenza vaccinemarket. The major reasons for the fastest growth in the region are massive unexplored market (as large number of people donot have access to vaccination), increasing involvement of government, and increasing healthcare expenditure.

Some of the major players operating in the global influenza vaccine market are GlaxoSmithKline,Sanofi Pasteur, Inc., ID Biomedical Corporation, CSL Limited, Novartis, Protein Sciences Corporaton, MedImmune, LLC, Sinovac Biotech, Serum Institute of India, and Hualun Biologicalsamong others.

Read More

Infectious Disease Treatment Market Outlook - Top Companies, Trends and Future Prospects Details for Business Development

Infectious diseases are medical conditions or disorders caused by microorganisms such as bacteria, fungi, viruses and other parasites. Several organisms are present in and on human bodies. Some organisms are normally harmless and even helpful. However, under certain circumstances, some organisms cause diseases. Infectious diseases spread from one person to another. Moreover, some are transmitted by bites from insects and animals. Infectious diseases also occur by consumption of contaminated food and water.

Signs and symptoms of infectious diseases depend on the type of organism and infection. Some of the most common symptoms of infectious diseases include fatigue and fever. Mild complaints of infectious diseases treated from rest and home remedies, while some life-threatening infections require hospitalization. Infectious diseases, such chickenpox and measles are prevented by vaccination. Frequent and thorough hand-washing also protect human body from infectious diseases.

Download Report Sample at:

North America dominates the global infectious disease treatment market followed by Europe. The U.S., followed by Canada, is the largest market for infectious disease treatment in the North American region. Key driving factor for infectious disease treatment market in the region is increasing research activities on various types of diseases. Germany, France and the U.K. are some of the largest markets for infectious diseases in Europe. However, Asia-Pacific represents the fastest growing region in the global infectious disease treatment market. This is due to minimal wages and availability of skilled professionals in the region. These factors attract drug manufacturing companies to invest in the Asian countries. In addition, in developing countries, such as China and India, government has launched several programs and initiatives to increase awareness about infectious diseases. China, Japan and India are largest infectious disease treatment markets in the region.

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=infectious-disease-treatment

Increasing prevalence of the infectious diseases is key driving factor for the global infectious disease treatment market. Increasing awareness and extensive R&D drugs pipelines are also enhancing the growth of global infectious disease market. Moreover, introduction of novel drugs, such as direct-acting antivirals, boosts the growth of global infectious disease treatment market.

However, patent expiry of various major drugs and presence of generic drugs are key restraint of the global infectious disease treatment market. Stringent regulations and legislations and side-effects of anti-infective drugs also hinder the growth of global infectious disease treatment market. Rapid product launches and increasing mergers and acquisitions between drug manufactures are emerging trends of the global infectious disease treatment market.

Some of the major competitors in the global infectious disease treatment market are F. Hoffmann-La Roche, GlaxoSmithKline, Merck, Johnson & Johnson, Pfizer, Gilead Sciences,  Bristol-Myers Squibb Company, AstraZeneca, Bayer AG, Novartis, Sanofi, AbbVie and Auritec Pharmaceuticals.

Read More

Chronic Lymphocytic Leukemia (CLL) Therapeutics Market Analysis by Stages, Drug Class, Company Profile, Phase of Development, and Discovery Stage Insights

The global chronic lymphocytic leukemia therapeutics market is expected to create more opportunities in oncology due to promising pipeline and positive clinical data of drug candidates. The existing drugs for the treatment of chronic lymphocytic leukemia is the be most effective treatment. The American Cancer Society, and other regulatory bodies are supporting the chronic lymphocytic leukemia therapeutics market by providing funding and grants. The market is being driven by different factors such as rising awareness for the cancer treatments, high demand for safe and effective medications, technologies advancements, and increasing prevalence of cancer.

Chronic lymphocytic leukemia is a type of gradually developing leukemia that affects the development of B lymphocytes (also known as B cells). On the other hand, B cells are specialized white blood cells, which produce immunoglobulins (also called antibodies) under normal conditions, and help to protect the human body against infections and diseases. In patients with chronic lymphocytic leukemia, lymphocytes undergo a malignant change and become leukemic cells.

Request to Get the Sample Pages at: 

Ono Pharmaceutical and Bristol-Myers Squibb are in the process of developing Opdivo for the treatment of chronic lymphocytic leukemia. Genentech is developing Atezolizumab, also known as MPDL 3280A, for chronic lymphocytic leukemia therapeutics, which is in Phase II stage. Atezolizumab is a monoclonal antibody targeting programmed cell death-1 ligand 1 (PD-L1). PD-L1 plays an important role in suppressing the immune system triggered by the cancer. PD-L1 acts by reducing the proliferation of antigen-specific CD8+ T-cells and controlling the accumulation of foreign antigen-specific T-cells.

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=chronic-lymphocytic-leukemia-therapeutics-market

The chronic lymphocytic leukemia is more prevalent in North America, making the region to be the largest revenue contributor, globally. The U.S. contributed the largest revenue to the North American market in year 2016, and it is expected to remain the largest market across the globe, during the forecast period.

Some of the key players operating in the chronic lymphocytic leukemia therapeutics market are GlaxoSmithKline plc, F. Hoffmann-La Roche AG, Celgene Corporation, Biogen Inc., AbbVie, Inc., Teva Pharmaceuticals Limited, Gilead Sciences, Inc., Novartis AG, and Johnson & Johnson.

Read More

Nuclear Medicine (Radiopharmaceuticals) Market by Overview, Growth Opportunities, Manufacturing Cost Structure Analysis, Outlook and Industry Insights Forecast to 2024

The global nuclear medicine/radiopharmaceuticalsmarket is growing significantly due to increasing prevalence of cancer and cardiovascular diseases, and advances in nuclear medicine imaging procedures. High demand of nuclear medicines in emerging economies and potential radiopharmaceuticals in the pipeline create ample opportunities for the nuclear medicine/radiopharmaceuticals market to grow at a considerable rate in the coming years.

The advances in neurological applications and development of new products by the companies are supporting to address the demand for cost effectiveness of radiopharmaceuticals. Nuclear medicine imaging procedures are non-invasive and can be used for the treatment of several diseases, such as cancers, cardiovascular diseases, and neurological disorders.

Request to Get the Sample Pages at: 

The nuclear medicine/radiopharmaceuticals market is segmented on the basis of type, application, and region. On the basis of type, the nuclear medicine/radiopharmaceuticals market can be segmented as diagnostics and therapeutics. The diagnostics segment leads the nuclear medicine/radiopharmaceuticals market. The diagnostics segment can be further categorized into single-photon emission computed tomography (SPECT) and positron emission tomography (PET). SPECT segment will be leading the nuclear medicine/radiopharmaceutical diagnostics market in the coming years due to its wider availability and less cost. The therapeutics segment can be further categorized into beta emitters, alpha emitters, and brachytherapy isotopes. The beta emitters will be the leading segment in the global nuclear medicine/radiopharmaceutical therapeutics market.

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=nuclear-medicine-market

Geographically, North America will be leading the global nuclear medicine/radiopharmaceuticals market in the coming years due to increasing prevalence of cancer, ready availability of radiopharmaceuticals, popularity of nuclear medicine among physicians, and technological advancements.

Asia-Pacific is the fastest growing region in the global nuclear medicine/radiopharmaceuticals market. The major reasons for the fastest growth in the region are increasing healthcare expenditure, and rising awareness of radiopharmaceuticals among healthcare providers. Moreover, Japan will be leading the nuclear medicine/radiopharmaceuticals market in Asia-Pacific region in the coming years.

Some of the major players operating in the global nuclear medicine/radiopharmaceuticals market are GE Healthcare, Bayer Healthcare, Cardinal Health Inc., Eczacibasi-Monrol Nuclear Products, Bracco Imaging S.p.A, Nordion Inc., Lantheus Medical Imaging Inc., Advanced Accelerator Applications S.A, Mallinckrodt plc, and IBA Molecular Imaging.

Read More

Human Growth Hormone Market Share, Strategies, Emerging Technologies, Growth Rate Analysis, Trends and Forecast

The global human growth hormone market is witnessing growth due to the presence of large pool of patients and technological advancements. The increasing compliance for human growth hormone drugs and massive unexplored market in the emerging economies, such as India and China are creating opportunities for the growth of the global human growth hormone market. The advanced research and development facilities, and new drug developments by the key players are propelling the demand for improved and cost effective human growth hormones; further fuelling the growth of the global growth hormone market.

Some of the factors driving the growth of the global human growth hormone market are increasing demand for human growth hormone drugs, increasing incidences of human growth hormone deficiency diseases, growing geriatric population, and technological advancements, such as recombinant DNA technology for the development of human growth hormone drugs. In addition, several major players are investing heavily and collaborating among each other for the research and development of human growth hormone drugs, which is fueling the growth of the global human growth hormone market. However, stringent regulatory approvals, high cost of treatment, and adverse effects associated with the usage of synthetic human growth hormones are some of the factors restraining the growth of the global human growth hormone market to some extent.

Request to Get the Sample Pages at:

Geographically, North America leads the global human growth hormone market, due to increasing proportion of aged population, high incidences of turner syndrome, short bowel syndrome, human growth hormone deficiency and Noonan syndrome. Moreover, the high demand of human growth hormone drugs as performance enhancer and anti-aging drug in North America is driving the growth of the human growth hormone market in the region. Asia-Pacific is the fastest growing region in the global human growth hormone market, which is driven by increasing healthcare expenditures and high incidences of growth hormone deficiency disorders. Moreover, the human growth hormone market is growing due to increasing disposable income and large geriatric population in the emerging countries, such as India and China.

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=human-growth-hormone-market

Some of the major players operating in the global human growth hormone market are Pfizer Inc., F. Hoffmann-La Roche AG, Novo Nordisk A/S, Merck KGaA, Eli Lilly and Company, Novartis AG, and Teva Pharmaceutical Industries Ltd.

Read More

Global Endometrial Cancer Therapeutics Market - Epidemiology Analysis, Therapy, Development, Growth and Demand Forecast to 2024

Global endometrial cancer therapeutics market is expected to witness significant growth as there are less number of approved drugs for treatment of endometrial cancer, leading to an increased opportunity for the drug manufacturers. High prevalence of cancer and rising demand for safe and effective medications can be attributed as the major drivers of this market. The regulatory bodies such as USFDA and EMA are supporting the growth of the global market by providing increased funding, designations and grants for speeding up the drug development process.

Endometrial cancer is the malignancy that develops in the layers of the cells that forms endometrium, lining of uterus. The precise cause of endometrial cancer is still unknown but it is assumed that estrogen may be involved in developing endometrial cancer, as estrogen helps in the formation of the endometrial lining. Obesity, polycystic ovary syndrome, infrequent periods and history of endometrial polyps can increase the risk of endometrial cancer. Women with diabetes, high blood pressure or breast cancer are at a greater risk of having endometrial cancer. Abnormal vaginal bleeding, bleeding between periods or after menopause, lower abdominal cramps or clear vaginal discharge after menopause are some of the main symptoms of endometrial cancer.

Request to Get the Sample Pages at:

High prevalence and recurrence of endometrial cancer after treatment with chemotherapy are the major driving factors driving the endometrial cancer therapeutic market.  Growing prevalence of obesity in women aged 50 years or above is also contributing in the growth of the endometrial cancer therapeutics market globally. Apart from this, safety concerns after chemotherapy, hormone therapy and radiation therapy restrict the medications for the treatment of endometrial cancer.

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=endometrial-cancer-treatment-market

Geographically, North America is expected to be the largest market for endometrial cancer therapeutics treatment, owing to the large number of research and development activities ad high healthcare expenditure. Europe is expected to hold the second largest share in the global market owing to growing product availability in the region.

Some of the key players operating in the global endometrial cancer therapeutics market are AstraZeneca Plc., Novartis AG, Bristol-Myers Squibb Company, Pfizer, Inc. and R-Pharm-US LLC.

Read More

Diabetic Nephropathy Market Opportunities by Types, Demand, Top Manufactures and Application in Grooming Regions

The increase in research and development funds for drug discovery followed by growing awareness of kidney-related disorders, and diabetes are the major factors driving the expansion of the global diabetic nephropathy market.

Diabetes is a disease defined by high blood sugar level, caused by inappropriate functioning of the pancreas (the organ which secretes insulin in the body). Nephropathy means kidney impairment or damage. Diabetic nephropathy is the impairment or damage to the kidneys caused by diabetes.

It is a disease which affects the kidney glomerulus and one of the most major issues for diabetic patients. Not only the person with diabetes has to undergo kidney impairment, but also the acute cases of diabetic nephropathy could lead to kidney miscarriage. The disease affects the kidneys in a way that makes it futile. Progressive growth in proteinuria and failure in renal function, hypertension, and high risk of cardiovascular disease are the major side effects of chronic diabetic nephropathy. Blood pressure (BP) control is necessary in minimizing the progression of diabetic nephropathy. Irrespective of the agent used, lower blood pressure in type II diabetics could slow down the start and progression of diabetic nephropathy.

Request to Get the Sample Pages at:

On the basis of mode of treatment, the global diabetic nephropathy market is segmented into disease modifying therapies and others. Disease modifying therapies is further categorized into diuretics, angiotensin-converting enzyme inhibitors, antioxidant inflammation modulator, angiotensin receptor blockers, renin inhibitors, calcium channel blockers, connective tissue growth factor inhibitors, monocyte chemoattractant proteins inhibitor, G protein-coupled receptors and endothelin (a receptor antagonist).

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=diabetic-nephropathy-market

Various government programs are spreading cognizance about diabetes and related renal complications in North America. For example, the National Kidney Disease Education Program (NKDEP) is one of the most important programs organized by the U.S. government, for growing awareness about the various kidney diseases.

Lack of complete therapeutic management for diabetic nephropathy, longer approval time for drugs as well as, harsh regulatory requirements are hampering the market growth of global diabetes nephropathy market.

Some of the major competitors in the global diabetic nephropathy market are Novartis AG, Merck & Co., Inc., Pfizer Inc., Abbott Laboratories, Sanofi, Eli Lilly and Company, Reata Pharmaceuticals, Inc., Bayer AG, AbbVie Inc., and Mitsubishi Tanabe Pharma Corporation.

Read More